The approval of novel oral therapeutic agents may offer a more cost-effective treatment option for acute myeloid leukemia.
A universal cancer gene therapy from the early 2000s is headed into phase 2 trials, in light of renewed interest and outlier patients who are still alive at 10 years later.
Research suggests that ibrutinib may have the ability to alter the phenotype of a final CAR-T cell product.
Despite a challenging toxicity profile, high dose interleukin-2 (HD IL-2), one of the earliest-approved immunotherapies for metastatic renal cell carcinoma still has a role in treating selected patients, a new registry analysis shows.
An Italian trial reported fewer deaths with annual or biennial low-dose CT lung screening—and an active surveillance approach reduced overdiagnosis.